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with usual activities and 23.6% of patients with mobility. Visual Analogue Scale 
(VAS) QoL scores for quiescent and active UC patients were 78.41 (14.89) and 69.50 
(19.41) (p= 0.0205), respectively. Quiescent patients had insignificantly better scores 
in all SIBDQ elements (global, systemic, social, bowel, emotional), global scores for 
patients with quiescent and active UC were 5.08 (1.31) and 4.75 (1.26) respectively. 
WPAI:UC indicated high levels of unemployment (40.7%). On average: work time 
missed (12.25% (27.30)), impairment while working (20.46% (25.85)) and overall work 
impairment (26.47% (32.21)). Scores for impairment of non-work activity for quies-
cent and active patients were 17.10% (25.45) and 27.39% (28.62) (p= 0.0244), respec-
tively. ConClusions: Patients with active UC demonstrated lower QoL measured 
by VAS and greater impairment of non-work activities. UC patients experienced a 
high percentage of unemployment and significant productivity loss.
Gastrointestinal DisorDers – Health Care Use & Policy studies
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Patterns of GeneriC anD ProPrietary PresCribinG of Proton PUmP 
inHibitors (PPis) over time in enGlanD
Hamilton K.A., Kusel J., Leonard S.A.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: Introduced in 2006 in England, the Better Care, Better Value (BCBV) indi-
cators aim to promote cost-effective prescribing in the NHS. Previous data presented 
at ISPOR showed that the total cost of statin prescriptions fell by 44% between 2007 
and 2012, and that much of this decrease was likely attributable to the prescription 
of generic atorvastatin following patent expiry of the proprietary form. This analysis 
aimed to evaluate patterns of proprietary prescribing of proton pump inhibitors (PPIs), 
another category of drugs identified by the BCBV indicators. Methods: Prescription 
Cost Analysis databases were reviewed (2007–2012). Data extracted were the number 
of prescription items dispensed yearly in the community in England for 5 commonly 
prescribed PPIs, the preparation class and net ingredient cost (NIC) of each item. 
The overall NIC (sometimes used as a proxy of budget impact to the NHS) for PPIs 
and the proportion of proprietary items prescribed each year for each drug were 
compared. Results: Between 2007 and 2012 the total NIC of PPIs decreased by 38%. 
Over the same period, the decrease in the proportion of proprietary prescriptions was 
greater for PPIs (78%) than previously reported for statins (65%); however, this did not 
translate into a greater saving in total NIC. This could be due to the higher average 
number of prescriptions per year and the higher average NIC per prescription item 
for statins than for PPIs. Analysing data for each PPI, we found dramatic decreases 
in proprietary prescribing (100% to < 11%) within two years following patent expiry 
of the proprietary form. ConClusions: There was a decrease in the proportion of 
proprietary prescribing of PPIs in England between 2007 and 2012, with rapid declines 
following patent expiry of proprietary drugs. This suggests that the BCBV indicator is 
being met for PPIs as well as for statins.
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objeCtives: IBD-specific quality measures calling for the use of steroid sparing regi-
mens (i.e., those involving anti-TNFs and non-biologic immunomodulators) were 
recently adopted by the Center for Medicare and Medicaid Services (CMS). However, 
many older patients have contraindications to anti-TNFs. Our objective was to 
describe drug utilization and patient characteristics among older IBD patients with 
anti-TNF contraindications. Methods: A retrospective cohort study was conducted 
using CMS’ national 5% sample for 2006-2009 including Medicare patients with ≥ 12 
months Parts A and B, ≥ 6 months Part D, an IBD diagnosis (≥ 2 claims for ICD-9CM 
555.xx or 556.xx) and contraindications to anti-TNFs (advanced CHF, malignancies). 
We described the prevalence and days of exposure to each IBD drug class. Patient 
characteristics associated with steroid exposure were examined using a negative 
binomial-logit hurdle model. Results: Among 10,362 patients, 18% (n= 1860; 53% 
CHF, 39% malignancy, 8% both CHF and malignancy) had contraindications to anti-
TNF therapy. The mean age was 79 years, 67% were female and 87% white. Steroid 
use ranged from 258-283 users per 1000 patients per year and averaged 123-145 mean 
annual treatment days for utilizers. Anti-TNFs and non-biologic immunomodula-
tors were used infrequently (anti-TNFs: 19-30 users per 1000 patients each year, 
non-biologic immunomodulators: 29-36 users per 1000 patients each year). Patients 
who were younger, white, receiving any IBD drug class except anti-TNFs, had poly-
pharmacy, more hospitalizations or absence of stroke history had greater odds of 
receiving steroids. Among steroid recipients, polypharmacy and anti-TNF use were 
associated with a 65% (23%-121%) and 79% (28%- 150%) greater number of steroid 
therapy days, respectively. ConClusions: Use of steroids exceeded steroid sparing 
regimens supporting the importance of the new quality measure as a strategy to 
improve care. Patients with anti-TNF contraindications are frequently appropriate to 
receive non-biologic immunomodulators and our findings suggest that these drugs 
are underutilized in this cohort.
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objeCtives: To assess the predictive value of patient-reported stool frequency and 
rectal bleeding for mucosal healing based on endoscopic evaluation in patients 
with active UC. Methods: Patients with active UC defined by a Mayo score of 6-12 
including an endoscopy subscore of ≥ 2 were randomized to receive placebo or goli-
mumab (GLM) 200mg/100mg or 400mg/200mg at weeks 0 and 2, respectively. Patient-
reported stool frequency and rectal bleeding from weeks 0 through week 6 were 
collected from the most recent consecutive 3-day period within the 2 weeks prior to 
the visit. Responder was defined as normalized stool frequency or no rectal bleeding. 
Mucosal healing is defined as an endoscopy subscore of the Mayo score of 0 or 1. 
Odds Ratio (OR), positive predictive value (PPV) and likelihood Ratio Positive (LR+) 
were estimated for predicting mucosal healing using normalized stool frequency 
or no rectal bleeding. Receiver Operating Characteristic (ROC) curve was developed 
based on different cut-off of combined stool frequency and rectal bleeding scores 
(0-6). Results: At week 0, 99% of patients reported abnormal stool frequency and 
86.9% reported rectal bleeding. Among patients who reported no rectal bleeding 
at week 6, 66.5% achieved mucosal healing compared to 16.0% of patients with 
rectal bleeding (OR= 9.9, p< 0.001, PPV= 0.65, LR= 3.0). Similarly, among patients with 
normalized stool frequency at week 6, 77.1% achieved mucosal healing vs. 32.8% % 
of patients with abnormal stool frequency at week 6 (OR= 6.9, p< 0.001, PPV= 0.77, 
LR= 5.3). On ROC curve, a cut-off of ≤ 2 on a combined stool frequency and rectal 
bleeding score resulted in a sensitivity of 85% and specificity of 70.6% for predicting 
mucosal healing at Week 6. ConClusions: Normalized stool frequency and no 
rectal bleeding are predictors for mucosal healing in patients with UC.
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objeCtives: To examine correspondences between PROs with changes in disease 
activity and treatment in patients with UC. PRO instruments assessed generic health-
related quality of life (HRQL; 12-item Short Form v2 [SF-12v2]), disease-specific HRQL 
(Shortened Inflammatory Bowel Disease Questionnaire [SIBDQ]), and work-related 
outcomes (WROs; Work Productivity and Activity Impairment Questionnaire: UC 
[WPAI:UC]). Methods: Adults with mild-to-moderate UC received MMX mesala-
mine 4.8 mg/d for 8 weeks in an open-label, prospective study (NCT01124149). PROs, 
and a modified UC-Disease Activity Index (UCDAI) that captured several symptoms, 
including stool frequency (SF) and rectal bleeding severity (RBS), were administered at 
baseline and Week 8. Spearman coefficients examined associations between changes 
in PROs and disease activity. Analysis of variance (ANOVA) models tested changes in 
scores over time, with Cohen’s d’s used to interpret effect sizes. ANOVAs examined 
PRO change scores as a function of improvement (≥ 1-point reduction) in SF and 
RBS. Results: 639 patients completed treatment. Change scores at Week 8 were 
large for SIBDQ (mean d = 0.93; range: 0.78, 1.16) and medium-to-large for SF-12v2 
(0.70; 0.52, 0.88) and WPAI:UC (–0.74; –0.34, –0.93). Changes in UCDAI total scores cor-
related most strongly with SIBDQ (average correlation = –0.41), followed by WPAI:UC 
(0.38) and SF-12v2 (–0.34). RBS improvement corresponded most strongly to SIBDQ 
(average d = 0.47) compared with SF-12v2 (0.41) and WPAI:UC (–0.38). SF improvement 
corresponded most strongly to WPAI:UC (average d = –0.67) versus SIBDQ (0.61) and 
SF-12v2 (0.58). ConClusions: Disease-specific HRQL showed greatest sensitivity to 
treatment and strongest response to improvements in RBS compared with generic 
HRQL or WROs. However, WROs showed the largest improvements in concordance 
with SF. PROs were more responsive to changes in SF than RBS. Results indicate that 
different PRO instruments, capturing different constructs, are sensitive to varying 
aspects of treatment-related improvements in UC disease activity.
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objeCtives: Ulcerative colitis (UC) is a chronic disabling condition associated with 
reduced quality of life (QoL). Little data exists on differences between patients with 
active versus quiescent UC regarding QoL and productivity loss. Methods: Patients 
with moderate/severe UC (Mayo score ≥ 6), ≥ 18 years who received conventional 
therapies during the previous year were recruited in Belgium, France, Germany, 
Greece, Italy, The Netherlands, Spain, Sweden, Switzerland, Turkey, and UK. Patients 
who received biologics, colectomy or ileo-anal J-pouch reconstruction were 
excluded. Patients were classified with quiescent or active UC; quiescence being 
clinical Mayo score ≤ 2, no sub-score> 1, no corticosteroids for two months or, if no 
endoscopy, partial Mayo score ≤ 2, no corticosteroids for two months. Patients com-
pleted EQ-5D-5L, Short Inflammatory Bowel Disease (SIBDQ) and Work Productivity 
Activity Impairment:UC (WPAI:UC) questionnaires. Quiescent and active patients 
were compared using chi-square and t-test. Results: 253 patients were included, 
mean (SD) age 46.6(16.2) years, 59% male, 250 patients completed questionnaires, 
218 (86%) had active UC. EQ-5D-5L indicated that 39.0% of patients had problems 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A41
Pms3
PrevalenCe of ComorbiDites amonG Patients witH Psoriasis (Pso) 
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1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
objeCtives: Assess the prevalence of comorbidities among PsO patients with PsA 
(PsO+PsA) and without PsA (PsO-alone) treated with biologics in UK/Germany/
France/Italy/Spain (5EU). Methods: A multi-country multi-center medical chart-
review study of PsO patients was conducted in 4Q2012 among physician (mainly-
dermatologists) in hospitals and private practices to collect de-identified data on 
patients who were recently treated with a biologic as part of usual care. Physicians 
were screened for duration of practice (3-30 yrs) and patient volume (incl. > 2 PsO 
biologic patients/month) and recruited from a large panel to be geographically rep-
resentative in each country. Physicians abstracted charts of next five consecutive 
patients within each center/practice, and collected patient diagnosis/symptomatol-
ogy, disease-severity (physician-judgment), comorbidities and treatment patterns/
dynamics. Prevalence of comorbidities among PsO+PsA and PsO-alone patients 
was evaluated. Results: 1064 eligible Psoriasis patients were included in the 
analysis (UK:19%, Germany:21%, France:21%, Italy:18%, SP:22%). Prevalence of PsA 
among PsO patients was: 13% (UK:13%, Germany:16%, France:15%, Italy:9%, SP:13%), 
thereby defining PsO+PsA(13%) and PsO-alone(87%) cohort size. Patient character-
istics differed between patient groups (All/PsO+PsA/PsO-alone)- age:48/49/47yrs; 
female:38%/46%.37%; in-remission:42%/48%/41%; mild-disease-severity:23%-
each; moderate-disease-severity:23%/18%/23%; severe-disease:13%/11%/13%; UK 
(20%) and Germany (30%) had disproportionately more severe patients within 
PsO+PsA and PsO-alone groups respectively. Comorbidities (> = 1) were observed 
in 55% of patients (UK:55%, Germany:52%, France:63%, Italy:44%, SP:59%); top-10 
comorbidities observed were (All/PsO+PsA/PsO-alone): obesity(20%/27%/19%), 
dyslipidemia(19%/21%/19%), diabetes(12%/19%/11%), anxiety(8%/10%/8%), heart 
disease(7%/6%/7%), depression(6%-per-group), liver disease(4%/8%/3%), migraine/
headache(2%/4%/2%), asthma(2%/3%/2%), osteoarthritis(2%/2%/1%). Skin cancer, 
IBD, ankylosing spondylitis and other respiratory conditions were ~1% each per 
group. Key comorbidity outliers were (country:All/PsO+PsA/PsO-alone): dyslipidemia 
(Spain:28%/40%/27%), obesity (Spain:24%/43%/21%), diabetes (France:16%/21%/15%), 
anxiety (France:17%/24%/15%), heart disease (Germany:15%/14%/15%), liver-disease 
(Spain:7%/17%/5%). ConClusions: Burden of comorbidities among Psoriasis 
patients is high, and significantly more so among subset of patients with PsA. This 
burden varied within 5EU. A multi-faceted approach to patient management is war-
ranted to manage these patients optimally and alleviate disease burden.
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objeCtives: The PALACE 1 study compared the efficacy and safety of apremilast 
(APR) with placebo in patients with active psoriatic arthritis despite prior conven-
tional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. The 
objective of the study was to assess the impact of APR therapy on physical func-
tioning in patients enrolled in the PALACE 1 study. Methods: Patients were rand-
omized 1:1:1 to placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified 
by baseline DMARD use (yes/no). Treatment efficacy was assessed at Week 16 based 
on the full analysis set population. Physical function, a pre-specified secondary 
end point, was measured in patients using the 36-item Short-Form Health Survey 
version 2 (SF-36v2) Physical Function (PF) domain, SF-36v2 physical component 
summary (PCS), and Health Assessment Questionnaire-Disability Index (HAQ-DI) 
scores. Results: 504 patients were randomized (49.4%: male; mean age: 50.4 years). 
At Week 16, the physical function change from baseline was significantly improved 
with APR30 vs. placebo, as measured by the SF-36v2 PF (4.23 vs. 1.81; P= 0.006), 
SF-36v2 PCS (4.59 vs. 2.39; P= 0.0097), and HAQ-DI (-0.244 vs. -0.086; P= 0.0017) scores. 
APR20 was associated with a significant improvement in the HAQ-DI score (-0.198 
vs. -0.086; P= 0.025), but not in the SF-36v2 PF (3.5 vs. 1.81; P= 0.050) and SF-36v2 PCS 
(3.53 vs. 2.39; P= 0.175) scores at Week 16. ConClusions: While both APR30 and 
APR20 showed a benefit in disability over 16 weeks, APR30 is consistently effective 
as measured by the improvement compared with placebo in the SF-36v2 PF, SF-36v2 
PCS, and HAQ-DI scores in patients with active psoriatic arthritis.
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ComParative effiCaCy of novel DmarDs as monotHeraPy anD in 
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objeCtives: To compare ACR responses between novel DMARDs, either as mono-
therapy or in combination with methotrexate (MTX), including subcutaneous (SC) 
abatacept and SC tocilizumab (TCZ), in RA patients with an inadequate response 
to conventional DMARDs (DMARD-IR). Methods: A systematic literature review 
identified 30 randomized clinical trials (RCTs) that evaluated abatacept (intravenous 
[IV] and SC), anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, inf-
liximab, tofacitinib, and TCZ (IV and SC). Reported treatment effects--ACR responses 
at 24 weeks--were synthesized by means of Bayesian network meta-analyses to 
compare the different treatments as monotherapy and combination therapy. The 
effects of anti-tumor necrosis factor (aTNF) therapy were assumed to be inter-
changeable. aTNF data were pooled. Results: The combination therapies aTNFs 
+ MTX, tofacitinib + MTX, abatacept IV/SC + MTX, and TCZ IV/SC + MTX dem-
onstrated comparable ACR responses while anakinra + MTX was less efficacious. 
objeCtives: Evaluate treatment patterns, health care utilization and costs of 
chronic hepatitis C (CHC) patients receiving direct-acting antiviral (DAA) protease 
inhibitors. Methods: Adult patients with ≥ 1 claim for CHC (ICD-9-CM codes 070.44, 
070.54, 070.70, 070.71) and a fill of boceprevir or telaprevir were selected from a 
de-identified US-based claims database (2006-2012). The date of the first fill for a 
DAA after 5/13/2011 (date of first DAA availability) was defined as the index date; 
patients were categorized into either the telaprevir or boceprevir cohorts. Patients 
had continuous eligibility and no claims for hepatitis B during the 6-months before 
(baseline) and 12-months following (study period) the index date. Baseline charac-
teristics and study period treatment patterns, health care utilization and costs were 
described. Adjusted study period costs were compared between the DAA cohorts 
using multivariate analyses. Results: There were 871 telaprevir and 284 boceprevir 
patients identified. DAA patients were 54 years old on average and more often male 
(62%). Approximately 25% of telaprevir and 18% of boceprevir patients had cirrhosis, 
and 9% of telaprevir and 7% of boceprevir patients had decompensated cirrhosis 
at baseline. Less than 1% of patients were HIV co-infected. Approximately 54% 
of telaprevir and 74% of boceprevir patients did not complete minimum recom-
mended therapy (telaprevir: 12 weeks of triple+12 weeks of dual, boceprevir: 4±1 
weeks of lead-in+24 weeks of triple). During the study period, over half of patients 
had anemia (boceprevir: 55%, telaprevir: 54%). Study period health care utilization 
measures were generally similar between the DAA cohorts. Telaprevir patients expe-
rienced numerically higher study period unadjusted medical (boceprevir: $16,927, 
telaprevir: $19,519) and drug costs (boceprevir: $59,953, telaprevir: $76,497) than 
boceprevir patients; however, after adjusting for baseline characteristics, only drug 
costs remained significantly different. ConClusions: CHC patients receiving 
telaprevir or boceprevir experienced high rates of early discontinuation and high 
medical and drug costs.
mUsCUlar-skeletal DisorDers – Clinical outcomes studies
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objeCtives: This study aims to explore medical care costs between cases with/
without hospital-acquired falls using prospective payment system data accord-
ing to ICD10. Methods: We had 23,336 in-patients with more than 16 years old 
between April, 2010 and March, 2012 at St. Mary’s Hospital in Kurume, Japan. There 
were 387 injured cases for falls. We examined length of hospital stay (LOS), Falls rate 
and medical care cost including medication and injection fee during hospitaliza-
tion. Results: We classified two groups, 387 injured cases with falls and 22,949 
cases without falls. The average age (mean ± standard deviation) were 72.0 ± 14.2 
years old for cases with falls and 59.7 ±20.3 y.o. for cases without falls. The LOS 
were 68.3 ±95.4 days and 18.9 ± 28.4 days. According to ICD10, LOS for Mental and 
Behavioral Disorders (F00-F99) was the longest (61.6 days) and Falls rate was the 
highest (90.9 1000pt･days). LOS for Factors influencing health status and contact 
with health services (Z00-Z99) among ICD10 codes and Falls Rate was the lowest 
(0 1000pt･days) among ICD10 codes. We assessed the highly positive association 
between length of hospital stay and Falls rate (y = 0.0016x - 0.013, R² = 0.8601). Total 
medical care cost were 26,971 USD for injured cases with falls and 9,937 USD for 
cases without falls, medication fee were 565 USD cases with falls and 162 USD for 
cases without falls, and injection fee were 2002 USD for injured cases with falls and 
670 USD for cases without falls. ConClusions: We realized the length of hospital 
stay is longer, Falls rate is higher and total medical care cost, medication fee, and 
injection fee are higher. In order to prevent hospital-acquired falls, we have to 
make assessments for falls and take an appropriate measure from the viewpoint 
of ICD10 codes.
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risk faCtors tHat PreDiCt nerve injUry followinG sPine sUrGery
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objeCtives: A technical nerve injury is a new or worsening nerve injury follow-
ing spine surgery. These injuries can be sub-categorized into cord injuries (new or 
worsening injury of the spinal cord or cauda equina injury), and radiculopathies 
(new or worsening sensory or motor deficit that follows the distribution of a specific 
nerve root). The goal of this study was to assess the risk factors that predict technical 
nerve injury from spine surgery. Methods: The Spine End Results Registry (SERR) 
is a prospective data registry of all patients (N= 1745) who underwent spine surgery 
from 1/1/2003 to 12/31/2004, at two academic hospitals. We modeled the predictive 
probability of various medical risk factors contributing to a technical nerve injury 
using a logistic random intercept model. The model was adjusted for diagnosis 
group, comorbidities, surgical invasiveness, age and gender, with a random inter-
cept term (surgeon), accounting for correlation, and a random slope (surgeon year 
of experience). A shrinkage estimator was used to predict the random effect of a 
surgeon. Surgical invasiveness is a score summed for the number of vertebral levels 
decompressed, arthrodesed, or instrumented, and surgical approach. Results: The 
adjusted multivariate regression analyses, the odds of a patient experiencing a tech-
nical injury was 0.008 (95% CI: 0.001, 0.042). The odds of a technical injury is < 1% for 
the average patient. No medical risk factors were significantly associated with the 
probability of experiencing a technical injury during surgery. The odds of a technical 
injury increased by 6% within a patient for each unit difference in surgical invasive-
ness (OR= 1.06, 95% CI: 1.03, 1.09, p < 0.001). ConClusions: There was insufficient 
evidence from the data to suggest that medical risk factors are associated with the 
probability of a technical injury. The highest probability of experiencing a technical 
injury following spine surgery is having a more invasive surgery.
